Michael J. Pishvaian, John L. Marshall, Andrew J. Wagner, Jimmy J. Hwang, Shakun Malik, Ion Cotarla, John F. Deeken, A. Ruth He, Hirut Daniel, Abdel-Baset Halim, Hamim Zahir, Catherine Copigneaux, Kejian Liu, Robert A. Beckman and George D. Demetri A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies Cancer 118
Article first published online: 8 MAY 2012 | DOI: 10.1002/cncr.27526
In this phase 1 study of efatutazone, a novel thiazolidinedione, fluid retention, manageable by diuretics, is a common side effect, and broad anticancer activity is demonstrated. Correlative studies show that tumor expression of peroxisome proliferator-activated receptor gamma and the retinoid-X receptor may serve as molecular markers to predict clinical benefit.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field